Attached files

file filename
EX-99.1 - NOTICE OF PROPOSED SETTLEMENT - SCICLONE PHARMACEUTICALS INCd245602dex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: October 20, 2011 (Date of earliest event reported)

 

 

SciClone Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-19825   94-3116852

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

950 Tower Lane, Suite 900, Foster

City, CA

  94404
(Address of principal executive offices)   (Zip Code)

(650) 358-3456

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On October 12, 2011 SciClone Pharmaceuticals issued a press release announcing the preliminary approval of a settlement of the consolidated derivative action against certain SciClone Pharmaceuticals current and former directors and officers, and against SciClone Pharmaceuticals as a nominal defendant. Subsequently, the California Superior Court for the County of San Mateo set a new hearing date of December 13, 2011 to consider final approval of the settlement. Pursuant to the Court’s order, the Company attaches hereto a revised Notice of Settlement as Exhibit 99.1 specifying the new hearing date.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 

99.1    Notice of Proposed Settlement, as revised

.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 20, 2011       SCICLONE PHARMACEUTICALS, INC.
      By:  

/s/ Friedhelm Blobel

        Friedhelm Blobel, Ph.D.
        Chief Executive Officer


Exhibit Index

Exhibit 99.1 Notice of Proposed Settlement